4 Fig. S3 . Changes in deuteration levels of the p85α nicSH 2 construct in the presence and absence of PDGFR phosphopeptide (complement to main figure 2). Peptides spanning the p85α regulatory 5 subunit that showed greater than 0.5 Da changes in deuteration level in the presence and absence of the nicSH 2 construct of p85α are colored onto the structures (2VIY, 2IUI, and 1H9O) according to the legend. The structures of phosphopeptide bound to the cSH2 and nSH2 domains are colored purple in the figure. Peptides are labeled A-M. The graphs are labeled (*) for any time point with a greater than 0.5 Da changes between the p110δ/ p85α nicSH 2 +/-PDGFR phosphopeptide.
6 Fig. S4 . Changes in deuteration levels of the free catalytic domain in the presence of both nicSH 2 p85α and PDGFR phosphopetide (complement to main figure 3). A. Peptides spanning the p110δ catalytic subunit that showed greater than 0.5 Da changes in deuteration level in the presence and 7 absence of the nicSH 2 construct of p85α are colored onto the structure (2WXH) according to the legend. Peptides are labeled A-I. B. Peptides spanning the p110δ catalytic subunit that showed greater than 0.5 Da changes in deuteration level in the presence of nicSH 2 +/-a PDGFR phosphopeptide are colored onto the structure according to the legend. The graphs are labeled (*) for any time points with a greater than 0.5 Da change between the ΔABD-p110δ and p110δ + nicSH 2 p85α constructs, and labeled (*) for any time point with a greater than 0.5 Da changes between the p110δ/ p85α nicSH 2 +/-PDGFR phosphopeptide.
8 Fig. S5 . Changes in deuteration levels of p110 catalytic subunit and p85α regulatory subunit in the presence of lipid vesicles (complement to main figure 5). A model containing the iSH2 domain of p85α and ABD domain of the catalytic subunit was generated by combining the ABD-p110 structure (2WXH) with the recently solved structure of p110α in complex with niSH2 (3HIZ) (Mandelker et al., 2009) . The c-terminal helix of the kinase domain that is disordered in p110 is modeled (region H) from the structure of p110γ (1E7U) (Walker et al., 1999 ) (A) Peptides spanning the p110δ catalytic subunit and the p85α regulatory subunit and that showed greater than 0.5 Da changes in deuteration level in the presence of lipid vesicles are mapped onto the model according to the legend. Peptides are labeled A-K. All experiments were performed in duplicate. The graphs are labeled (*) for any time points with a greater than 0.5 Da change between p110δ+nicSH2 + pY in the presence of 1mg/ml of 5% PIP2 lipid vesicles. In this example, peptide 1023-1033 covers an extremely flexible region that shows ~50% relative exchange (the real value will be 20-30% greater due to back exchange) in the ΔABD-p110δ after 3 seconds. The presence of the nicSH2 construct of p85α causes a decrease in exchange, and this decrease is reversible with pY peptide. However, this region is ~50% exchanged after 10 seconds of on-exchange, even in the presence of the nicSH2 construct indicating that this region remains highly flexible and solvent exposed relative to other regions in the protein. Peptide 524-529 represents a different situation where the peptide is completely protected in all conditions through 10 seconds of on exchange. After this time constructs lacking the nSH2 or cSH2 show a progressive incorporation of deuterium up to ~40-50% at 1000 seconds. The presence of the nicSH2 construct prevents all exchange through 100 seconds and this decrease is reversible with pY peptide, but after this time deuterium incorporation begins. However even at 3000 seconds there is still significant protection by the nicSH2 compared to the free subunit. This indicates that this region is conformationally rigid or solvent protected in the p85α bound state, and that the removal of this contact by removal of the SH2 domains or pY peptide binding exposes this region; however the region remains relatively rigid compared to a region like 1023-1033.
Tab. S1 Summary of all peptides analyzed for p85 constructs, pY peptide binding, and lipid binding. 
SI Materials and Methods
Protein expression and purification.
The ΔABD-p110δ was expressed as previously described (Berndt et al., 2010) . In short for expression of all protein complexes 1 to 8 liters of Spodoptera frugiperda (Sf9) cells at a density of 1.0x10 6 cells/mL were co-infected with an optimized ratio of viruses encoding complexes of the catalytic and regulatory subunit. The catalytic subunit contained an N-terminal 6xhis-tag followed by a TEV protease site, while the regulatory subunit was untagged. After 48-63 hr infection at 27˚C, cells were harvested and washed with ice-cold phosphate-buffered saline (PBS). The ΔABD-p110δ was expressed as a complex of the full length p110δ with a TEV protease site engineered after the ABD domain with the iSH2 domain of p85α The Sf9 cell pellets were lysed in 100 mls of 20 mM Tris pH-8.0, 100 mM NaCl, 5% glycerol, 10 mM Imidazole, and 2 mM β-mercaptoethanol, with one complete EDTA free protease inhibitor tablet added(Roche). Cells were lysed with a 4 minute probe sonication followed by centrifugation for 30 minutes at 140,000 g. The supernatant was then passed through a 0.45 µm Minisart filter unit (Sartorius Biotech). This filtrate was then passed over one 5 ml HisTrap FF column (GE healthcare). The column was washed with up to 30 mM imidazole and then eluted with a gradient of 0-100% buffer B (20 mM Tris pH-8.0, 100 mM NaCl, 5% glycerol, 300mM
Imidazole, and 2 mM beta-mercaptoethanol). The pooled fractions were then added onto a 5 ml Heparin HP column (GE healthcare) and washed with buffer C (20 mM Tris pH 8, 100 mM NaCl, 2 mM DTT) and eluted with a 0-100% gradient of buffer D (20mM Tris pH 8, 2 mM DTT, 1 M NaCl).
The ΔABD-p110δ construct was generated by an overnight incubation with a 1:10 w/w ratio with TEV protease in the presence of 10 mM β-mercaptoethanol. All other p110δ/p85α heterodimers still contained the N-terminal his-tag, however kinase assays on p110δ/p85α nicSH2 heterodimers with and without the 6xhis-tag removed by TEV cleavage showed similar results (Data not shown). Both the ΔABD-p110δ or p110δ/p85α heterodimers were then concentrated to 1.5 ml using a amicon 50k centrifugal filter (Millipore) and injected on a Superdex 1660 gel filtration column (GE healthcare) pre equilibrated with buffer E (20 mM Tris pH-7.2, 50 mM ammonium sulfate, 1% ethylene glycol, and 5 mM DTT). Fractions were collected and concentrated to 30 µM using a amicon 50k centrifugal filter (Millipore) and then aliquoted and frozen in liquid nitrogen.
Lipid vesicle preparation
Vesicles were prepared by adding the lipid components together in chloroform and evaporating organic solvent under a stream of dry argon. The lipid film was allowed to dry for thirty minutes under vacuum, and was then resuspended in a 20 mM Tris pH-7.5, 100 mM KCl, and 1 mM EGTA solution. The lipids were first bath sonicated for ten minutes, and then subjected to ten cycles of freeze-thaw between liquid nitrogen and a 42 °C water bath. The liposomes were finally extruded eleven times through a 100 nm filter using a mini extruder (Avanti Polar Lipids). Vesicles were frozen at -80 ºC and used within one week of preparation.
Protein lipid FRET assays
Vesicles were prepared exactly the same as above except with the inclusion of 10% dansyl PS (Avanti polar lipids). Two different types of lipid vesicles were prepared, one with 5% PIP2 (5% brain PIP2, 20% brain PS, 10% Dansyl PS, 35% brain PE, 15% brain PC, 10% cholesterol, and 5% sphingomyelin), and one with 0% PIP2 with the extra lipid composed of brain PS (25% brain PS, all other components the same). Protein solutions were allowed to preincubate with 10 µM pY peptide for 10 minutes before addition of lipid vesicles. Vesicles were 5 fold diluted with 20 mM tris pH-7.5, 100 mM NaCl, to give a concentration of to 200 µg/ml. 5 µl of the lipid mixture was mixed with 5 µl of a varying concentration of protein constructs, giving a final buffer of 100 µg/ml lipid, 20 mM tris pH-7.5, 90 mM NaCl, 10 mM KCl, 100 µM EGTA. The protein lipid mixture was allowed to equilibrate for 15 minutes. Reactions were measured using a PHERAStar HTS microplate reader (BMG Labtech) using a 280 nm excitation filter with 350 nm and 520 nm emission filters to measure Trp and Dansyl-PS FRET emissions, respectively. The FRET signal shown on the Y-axis is (I-I 0 ), where I is the intensity at 520 nm, where I 0 is the intensity for a solution with lipid only (without protein).
Akt phosphorylation assay
Phoenix cells (HEK-derived cells, Orbigen) grown in 35 mm-diameter wells were transfected with pMIG vectors (Kulathu et al., 2008) expressing myc-p110δ and FLAG-p85 wild-type or mutant using Genejuice (Novagen) as described by the manufacturer. Cells were grown for 24 h, starved for 21 15 h in serum-free media and lysed with ice-cold lysis buffer [20 mM Tris-HCl pH 7.4, 150 mM sodium chloride, 1 mM EDTA, 1 mM EGTA, 1% Nonidet P40 (BDH laboratories), 2.5 mM sodium 
Measurement of deuterium incorporation
Samples were thawed rapidly on ice and then injected onto an online HPLC system that was immersed in ice. The protein was run over an immobilized pepsin column (Applied Biosystems, Poroszyme®, 2-3131-00) at 100 µl/min, and collected over a C18 peptide trap (Michrom, TR1/25109/2) for five minutes. The trap was then switched in line with a 5 µm particle, 50 mm x 1 mm C18 column (Discovery sciences, 218MS5105) with a guard column and peptides were eluted by a 5-45% gradient of buffer A (0.1% formic acid) and buffer B (80% acetonitrile, 20% H 2 O, 0.02% formic acid) over thirty minutes and injected onto a Sciex QStar Pulsar hybrid QqTOF (Applied Biosystems) which collected mass spectra from a range of 350 to 1500 m/z. Lipid binding, nucleotide binding, and p85 point mutation experiments were performed with an online UPLC system which replaced the C18 peptide trap with a 1.7 µm particle van-guard pre column (Waters), and used an Acquity® 1.7 µm particle, 100 mm x 1 mm C18 column (Waters). The UPLC system allowed separations to be carried out with a 20 minute gradient from 5-45% B. Mass analysis of the peptide centroids was performed as described previously using the software DXMS (Sierra Analytics) and is described below (Fig S7) (Burke et al., 2008) . For lipid binding experiments there was concern that the lipid might cause problems with UPLC performance and possible ion suppression. Our experiments showed that the lipid was retained on the column throughout the run with no negative effects on UPLC column performance (Fig. S7) . The entire UPLC setup was flushed with 80% acetonitrile for 30 min at the end of the experiment to fully elute all lipid. The UPLC setup allowed for a faster and more efficient peptide separation, however this did cause changes in back exchange rates compared to HPLC runs. For this reason none of the comparisions in the manuscript were performed between HPLC and UPLC experiments, and were only performed under similar experimental protocols.
Protein digestion and peptide identification
Different digestion conditions were employed to optimize the peptide digestion map. These optimizations included changing denaturant concentration, flow rate over pepsin, and denaturation time (See below for optimal conditions). Peptide identification was performed by running tandem MS/MS experiments using a Sciex QStar Pulsar hybrid QqTOF (Applied Biosystems). IDA (information dependent acquisition) MS/MS experiments were performed with Analyst 2.0 with a 1 second TOF MS scan from 350-1500 m/z followed by two 1.5 second product ion scans with a capillary voltage of 5300 V. Data was analyzed using Mascot software v. 2.2 (Matrix Science) to identify peptides based on fragmentation and peptide mass. The MS tolerance was set at 30 ppm with a MS/MS tolerance of 0.2 Da. All peptides with both a mascot score >10 and a parent mass error smaller than 20 ppm were analyzed by the DXMS software (Sierra Analytics). Any peptides with a mascot score from 10 to 20 were further manually checked to see if there were any possible false identifications, and any ambiguous peptides were deleted from the peptide pool. The total list of peptides were then manually validated by searching a non deuterated TOF MS scan to test for correct m/z state, and check for the presence of overlapping peptides. Although the DXMS software was used to automate the initial analysis aftwewards every peptide shown in the paper was manually verified at every timepoint and replicate to check for correct charge state, m/z range, presence of overlapping peptides, and proper retention time.
Mass analysis of peptide centroids
All selected peptides passed the quality control threshold of the DXMS software, and were then manually examined for accurate identification and deuterium incorporation. There was a correction for on-exchange made by adding deuterium after the quench buffer was added. This value was subtracted from all deuterium exchange experiments. For this reason some peptides have a negative value of exchange in Table S1 . Attempts were made at generating a fully deuterated sample, but were not successful, and for this reason results are shown as relative levels of deuteration with no correction for back exchange as described previously (Iacob et al., 2009 ). The only correction made was correcting for the level of deuterium in the exchange buffer (82%) (66% in lipid binding experiments). The real level of deuteration will be ~25-35% higher than what is shown, based on tests performed with fully deuterated standard peptides. All experiments were repeated in duplicate, and we found that the average error was ≤0.2 Da for non-corrected data, and for this reason we consider all non corrected changes between conditions of greater than 0.5 Da significant. The resulting deuterium incorporation was graphed versus the on-exchange time. The 3 seconds at 0 º C time point was graphed as 1 second in all on-exchange graphs to fit all data to the same graph. Full deuterium exchange methodology is described ( Figure S7) , and all deuterium exchange data for all peptides analyzed for phosphopeptide / p85 constructs (~240 peptides) is shown in tabular form (Tab. S1A, S1B). For lipid binding experiments we used less protein to maximize the ratio of lipid to protein. For this reason fewer peptides were able to be followed, but still over 150 peptides between the catalytic and regulatory subunit were quantified for deuterium incorporation (Tab. S1C).
